^
    Back
    Association details:
    Biomarker:TSC1 mutation
    Cancer:Bladder Cancer
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Science
    Title:

    Genome sequencing identifies a basis for everolimus sensitivity

    Excerpt:
    Targeted sequencing revealed TSC1 mutations in about 8% of 109 additional bladder cancers examined, and TSC1 mutation correlated with everolimus sensitivity.
    DOI:
    10.1126/science.1226344
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Science
    Title:

    Genome Sequencing Identifies a Basis for Everolimus Sensitivity

    Excerpt:
    Patients with TSC1-mutant tumors remained on everolimus longer than those with wild-type tumors (7.7 versus 2.0 months, P= 0.004) with a significant improvement in time to recurrence (4.1 versus 1.8 months; hazard ratio = 18.5, 95% confidence interval 2.1 to 162, P = 0.001).
    DOI:
    10.1126/science.1226344